Infectious Disease Therapeutics Market size valued USD 121.4 billion in 2021 and expected to reach USD 166.32 billion by 2028, at a CAGR of 4.6% during the forecast period 2022-2028. Infectious diseases are caused by organisms, such as bacteria, virus, fungi or parasites. Many organisms live in our body but few of them cause diseases. These infectious diseases are transmitted from one individual to other either by direct or indirect contact. The drugs used for infectious diseases are antibiotics, antiviral, and antiparasitic, among others. Infectious disease therapeutics acts directly on organisms or helps the body system to fight infections. Infectious diseases include HIV, malaria, tuberculosis, hepatitis, and influenza, among others. Market players focus on mergers, acquisitions and collaborations to increase revenue share in the market. For instance, in August 2016, Pfizer acquired AstraZeneca’s late-stage small molecule anti-infectives business for development and commercialization outside the U.S. In addition, market players investing on research and development to introduce new drugs and to strengthen their position in the infectious disease therapeutics market. Some of the pipeline anti-infectives include avycaz (ceftazidime and avibactam), bictegravir (Anti HIV), cabotegravir (Anti HIV). Patent expiry of blockbuster anti-infectives such as Tamiflu, cubicin and ambisome are expected to negatively effect the infectious disease therapeutics market.
In July 2017, Gilead’s “vosevi” oral tablet was approved by U.S. FDA for treatment of adults with chronic hepatitis C virus
In March 2015, U.S. Food and Drug Administration approved cresemba (isavuconazonium sulfate), a novel antifungal drug for treat adults with invasive aspergillosis and invasive mucormycosis, rare but serious infections
In December 2014, Sanofi Pasteur announces FDA approval of fluzone intradermal quadrivalent (Influenza Vaccine) for adults.